Critical Care Alert – January 1, 2021
January 1, 2021
View Issues
-
A Review of Current Therapeutics for Severe COVID-19 Pneumonia
The aim of this special feature is to review therapeutic options for hospitalized patients with COVID-19 pneumonia.
-
Convalescent Plasma Therapy Does Not Affect Time to Clinical Improvement in Patients with Severe and Life-Threatening COVID-19
This was a randomized, open-label, multicenter trial of intravenous convalescent plasma infusion (4 mL/kg to 13 mL/kg) therapy. Convalescent plasma therapy was not associated with improvements in mortality or time to clinical improvement.
-
Patients with Higher Renin Levels May Derive More Benefit from Angiotensin II Treatment
Serum renin concentration in patients with catecholamine-resistant vasodilatory shock may identify those for whom treatment with angiotensin II has improved intensive care unit outcomes.